Page last updated: 2024-12-08
Gamabufogenin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
gamabufotalin: antiangiogenic, main active compound isolated from Chinese medicine Chansu; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 259803 |
| CHEMBL ID | 465318 |
| CHEBI ID | 80826 |
| SCHEMBL ID | 866038 |
Synonyms (35)
| Synonym |
|---|
| nsc-90384 |
| gamabufagin |
| bufa-20, 3,11,14-trihydroxy-, (3.beta.,5.beta.,11.alpha.)- |
| gammabufotalin |
| 5.beta.-bufa-20, 3.beta.,11.alpha.,14-trihydroxy- |
| gamabufogenin |
| 465-11-2 |
| nsc90384 |
| gamabufotalin |
| 3-beta,11-alpha,14-trihydroxy-5-beta-bufa-20,22-dienolide |
| bufa-20,22-dienolide, 3,11,14-trihydroxy-, (3-beta,5-beta,11-alpha)- |
| 5beta-bufa-20,22-dienolide, 3beta,11alpha,14-trihydroxy- |
| 5-beta-bufa-20,22-dienolide, 3-beta,11-alpha,14-trihydroxy- |
| nsc 90384 |
| C16962 |
| chebi:80826 , |
| CHEMBL465318 |
| 5-[(3s,5r,8r,9s,10s,11r,13r,14s,17r)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one |
| unii-5hh3km165o |
| 5hh3km165o , |
| A827057 |
| SCHEMBL866038 |
| CS-3701 |
| AC-34676 |
| Q-100490 |
| (3.beta.,5.beta.,11.alpha.)-3,11,14-trihydroxybufa-20,22-dienolide |
| gamabufotalin [mi] |
| HY-N0883 |
| AKOS030526148 |
| NCGC00485918-01 |
| Q27149869 |
| gamabufalin |
| mfcd01740822 |
| DTXSID40878664 |
| AS-77298 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Even at the highest dosage tested, Nerodia showed no effects, whereas the lowest dose was lethal to Pituophis." | ( Mutations to the cardiotonic steroid binding site of Na(+)/K(+)-ATPase are associated with high level of resistance to gamabufotalin in a natricine snake. Brodie, ED; Mohammadi, S; Neuman-Lee, LA; Savitzky, AH, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| steroid lactone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID357629 | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. |
| AID357628 | Cytotoxicity against human KB cells after 72 hrs by MTT assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. |
| AID155909 | Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/5 | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1). |
| AID155910 | Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/5 | 2002 | Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25 | QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1). |
| AID357630 | Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||